kabutan

Sumitomo Pharma Co., Ltd.(4506) Summary

4506
TSE Prime
Sumitomo Pharma Co., Ltd.
2,469.5
JPY
+34.0
(+1.40%)
Dec 5, 11:30 am JST
15.92
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
2,467.1
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
10.6
PBR
3.69
Yield
ー%
Margin Trading Ratio
4.82
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
2,432.5 JPY 15.68 USD
Previous Close Dec 4
2,435.5 JPY 15.67 USD
High Dec 5, 10:39 am
2,478.0 JPY 15.98 USD
Low Dec 5, 9:00 am
2,413.0 JPY 15.55 USD
Volume
3,548,100
Trading Value
8.69B JPY 0.06B USD
VWAP
2449.02 JPY 15.79 USD
Minimum Trading Value
246,950 JPY 1,592 USD
Market Cap
0.98T JPY 6.34B USD
Number of Trades
9,822
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
8,600
1-Year High Nov 5, 2025
69,972
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 912,100 6,424,100 7.04
Nov 21, 2025 898,700 6,571,500 7.31
Nov 14, 2025 946,000 6,296,500 6.66
Nov 7, 2025 775,800 6,763,500 8.72
Oct 31, 2025 748,300 6,856,800 9.16
Company Profile
Sumitomo Pharma Co., Ltd. is a mid-sized pharmaceutical company originating from the Sumitomo Chemical group. The company focuses on developing drugs in the areas of psychiatry and neurology, oncology, and regenerative medicine.
Sector
Pharmaceuticals
Sumitomo Pharma's core business is the manufacturing, procurement, and sales of prescription pharmaceuticals, while also dealing with medical devices. The company prioritizes psychiatry, neurology, and oncology as its key therapeutic areas. In Japan, Sumitomo Pharma conducts manufacturing and sales of prescription pharmaceuticals through its subsidiaries. Additionally, through a joint venture with its parent company Sumitomo Chemical, it engages in contract development and manufacturing in the field of regenerative medicine and cell therapy. Sumitomo Pharma is also actively expanding globally, with operations in North America, China, Southeast Asia, and Taiwan. The company has established subsidiaries in various regions to conduct local pharmaceutical manufacturing, sales, and information provision activities.